MARK3
Summary: The protein encoded by this gene is activated by phosphorylation and in turn is involved in the phosphorylation of tau proteins MAP2 and MAP4. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| microtubule affinity regulating kinase 3 | MIM:602678 | Ensembl:ENSG00000075413 | HGNC:HGNC:6897 | PA30640 | 14q32.32-q32.33 |
GO terms in MARK3
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IBA | GO:0004674 | protein serine/threonine kinase activity |
| MF | IDA | GO:0004674 | protein serine/threonine kinase activity |
| MF | NAS | GO:0004674 | protein serine/threonine kinase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IBA | GO:0050321 | tau-protein kinase activity |
| MF | IMP | GO:0050321 | tau-protein kinase activity |
| CC | IBA | GO:0005737 | cytoplasm |
| CC | IDA | GO:0005737 | cytoplasm |
| CC | NAS | GO:0005737 | cytoplasm |
| CC | TAS | GO:0005829 | cytosol |
| CC | IBA | GO:0005886 | plasma membrane |
| CC | IDA | GO:0005886 | plasma membrane |
| CC | IDA | GO:0030425 | dendrite |
| CC | HDA | GO:0070062 | extracellular exosome |
| BP | TAS | GO:0000165 | MAPK cascade |
| BP | IBA | GO:0000226 | microtubule cytoskeleton organization |
| BP | IMP | GO:0006468 | protein phosphorylation |
| BP | IDA | GO:0018105 | peptidyl-serine phosphorylation |
| BP | IDA | GO:0032092 | positive regulation of protein binding |
| BP | IDA | GO:0035331 | negative regulation of hippo signaling |
| BP | IBA | GO:0035556 | intracellular signal transduction |
| BP | IDA | GO:0036289 | peptidyl-serine autophosphorylation |
Gene expression in normal tissue: MARK3
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MARK3
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5673000 | RAF activation |
| reactome | R-HSA-5673001 | RAF/MAP kinase cascade |
| reactome | R-HSA-5674135 | MAP2K and MAPK activation |
| reactome | R-HSA-5675221 | Negative regulation of MAPK pathway |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5684996 | MAPK1/MAPK3 signaling |
| reactome | R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants |
| reactome | R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants |
| reactome | R-HSA-6802949 | Signaling by RAS mutants |
| reactome | R-HSA-6802952 | Signaling by BRAF and RAF fusions |
| reactome | R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| reactome | R-HSA-6802957 | Oncogenic MAPK signaling |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD280 | CYTOCHALASIN B | 4 |
| iGMDRD394 | BX-795 | 3 |
| iGMDRD193 | Fqi1 | 2 |
| iGMDRD446 | LY 2183240 | 4 |
| iGMDRD560 | MK-2206 | 3 |
| iGMDRD424 | Tamatinib | 2 |
| iGMDRD420 | Leucascandrolide A | 2 |
| iGMDRD64 | Parbendazole | 2 |
| iGMDRD369 | TGX-115 | 2 |
| iGMDRD329 | Merck60 | 1 |
| iGMDRD100 | Zebularine | 2 |
| iGMDRD399 | Selumetinib | 3 |
| iGMDRD77 | Itraconazole | 2 |
| iGMDRD294 | Batimastat | 2 |
| iGMDRD187 | BRD9876 | 1 |
| iGMDRD434 | BMS-536924 | 1 |
| iGMDRD255 | SB225002 | 3 |
| iGMDRD513 | BML-259 | 1 |
| iGMDRD121 | GMX1778 | 2 |
| iGMDRD158 | NSC141540 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MARK3
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.